At a glance
- Dulaglutide is an FDA-approved drug, marketed as Trulicity (first approval: September 18, 2014).
- PubMed lists 1,332 publications mentioning it, including 147 randomized controlled trials and 49 animal-only studies.
- ClinicalTrials.gov lists 143 registered studies testing it (24 active).
- FDA's adverse event system (FAERS) holds 88,461 reports mentioning it; 23,096 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| BLA125469 | TRULICITY | Approved, marketed | September 18, 2014 | ELI LILLY AND CO |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Combined administration of buntanetap and dulaglutide counteracts synaptic dysfunction and memory loss in an Alzheimer's disease mouse model.
- Single or multiple nutritional hormone receptor modulators for chronic kidney disease.
- GLP-1 receptor activation attenuates chronic migraine-like behaviour: Sex-specific modulation of opioid- and endocannabinoid-related pathways.
- Comparison of cardiac adverse event signal profiles for GLP-1 receptor agonists: an analysis of the FAERS database.
- Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance.
- Beyond Weight Loss and Glycemic Control: Molecular Mechanisms and Hypothesis-Generating Therapeutic Potential of Incretin-Based Therapies Against Peritoneal Fibrosis in Peritoneal Dialysis.
- Target Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis.
- Knowledge, attitudes, and practices among users of GLP-1 receptor agonists in Saudi Arabia: a cross-sectional study.
- Oral Health-Related Adverse Events of GLP-1 Receptor Agonists.
- Glucagon-like Peptide-1 Receptor Agonists in Heart Transplant Recipients With Type 2 Diabetes: A Multicenter Study.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 143
- Active
- 24
- With posted results
- 61
Conditions studied
Show 40 more studies
All 143 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 88,461
- Serious
- 23,096
- With death outcome
- 1,698
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
Original FDA text (English) WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), and Nonclinical Toxicology ( 13.1 )] . TRULICITY is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of TRULICITY and inform them of symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with TRULICITY [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )] . WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. Dulaglutide causes thyroid C-cell tumors in rats. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined ( 5.1 , 13.1 ). TRULICITY is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors ( 4 , 5.1 ). Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.